Seeking Alpha

Prohost Biotech

 
View as an RSS Feed
View Prohost Biotech's Comments BY TICKER:
Latest  |  Highest rated
  • Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie [View article]
    Out of this seemingly serious debate, fiction, sometimes, must interfere and you imagine yourself sitting at your dining room table looking at biotechnology companies' websites. You ask your wife if she can make you coffee so you can focus better on what you see. In one of the firms, you observe two drugs being developed for the same disease. You call your savvy wife and ask her: Wouldn't be more effective if this firm combines these two drugs in one pill? She agrees. You run to the patent office the next day and patent the idea while nobody there tells you that the owner and developer of the two drugs have already filed for a patent.

    Nevertheless you are handed the patent and after sometime you filed a law suit against the developer of the drug asking for a cut.

    In this story, the judge granted you the right to have a consultation fee, but on condition that you prove that you offered the developing firm the idea of putting the two products in one.

    the questions are:

    1. Can you prove that you are the source of the firm's idea behind the creation of its all-oral product?

    2. In case you can do it, then how much do you think the fees could be?

    3. Do you think, if granted, the fees would really hurt the firm's revenues, knowing in fact that the drug will generate tens of billions of dollars a year?

    4. Would you ask the Judge to change the fees to an annual royalty for doing nothing?
    Nov 13, 2014. 02:59 PM | Likes Like |Link to Comment
  • Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie [View article]
    Harvoni is Gilead's proprietary drug, it was approved for Gilead, which conducted all the possible and imaginary trials to demonstrate the superiority of this combination pill over all other HCV drugs. This article raised our expectations from believing that Harvoni will become "the best HCV selling drug on the market", into believing that the pill will dominate the whole HCV market. When that will happen, AbbVie would deserve the charity some believe it might be entitled to.
    Nov 13, 2014. 11:03 AM | 1 Like Like |Link to Comment
  • Regulus Therapeutics' RG-101 Poses Liver Cancer Risk [View article]
    RG-101 results are stunning. But the drug is still in very early stage of development. A lot of factors are involved towards the final outcome of drugs, especially the new categories of therapeutic molecules that have little history. Most above discussions is speculative. The debaters are trying to use logic, yet not based on evidence-based scientific facts as they are non-existent at this early phase of the clinical trial.

    Our opinion on the RG-101 has already been expressed in the beginning of this comment and our opinion on Regulus is that it is scientifically sound and will have a great future. This opinion will remain the same even if one of its investigational drugs would fail to replicate its stunning early results.
    Oct 24, 2014. 11:09 PM | 1 Like Like |Link to Comment
  • Illumina's (ILMN) CEO Jay Flatley On Q3 2014 Results - Earnings Call Transcript [View article]
    We congratulate Illumina and ourselves having such a great innovative, highly scientific and greatly managed company. We said it a few years ago and we repeat that, indeed, Illumina is the powerful engine behind the success of biotechnology industry in realizing the dream of researchers and clinicians. The future will see great changes in pinpointing real evidence-based facts over which evidence-based medicine will be practiced.
    Oct 21, 2014. 08:24 AM | 3 Likes Like |Link to Comment
  • Gilead's Sovaldi Is The Solution, Not The Problem [View article]
    Gary ... and eliminate years of torture, of hospitalization, of liver cirrhosis ... of ... hospitalization ... of liver failure ,,,, hospitalization.... liver transplant ''' hospitalization... transplanted liver HCV infection again ... mental and physical torture ... hospitalization ... or liver cancer ... several hospitalizations .. attempts to treat ... failure to treat ... and death.

    That's what Sovaldi and the fixed dose all-oral combination that will be approved soon do elimminate
    Aug 1, 2014. 06:17 PM | 1 Like Like |Link to Comment
  • Gilead's Sovaldi Is The Solution, Not The Problem [View article]
    You are right and referring to the inaccuracy was important. Thanks CSYJ.
    Apr 29, 2014. 03:32 PM | Likes Like |Link to Comment
  • Theravance: Baby Thrown Out With The Bath Water - 35% To 65% Upside [View article]
    Fair analysis and meaningful discussions and comments. Indeed the reward outweigh the risk and asthma and COPD are chronic debilitating and life-threatening diseases. The new inhalers, especially the long-acting have made a big difference in the management of these diseases, improving by far their prognosis. Badly managed, both asthma and COPD become torturing and the cost becomes exorbitant,considering the required frequent hospitalization.

    Thanks for the article and the savvy commentators.
    Apr 19, 2014. 02:40 AM | Likes Like |Link to Comment
  • Are You Betting Too Much On Theravance? [View article]
    Such formidable debates do not exist anywhere except at Seeking Alpha stage. Such discussions are very revealing and helpful for investors.
    Apr 18, 2014. 09:23 AM | Likes Like |Link to Comment
  • Prosensa: Back Into The Limelight [View article]
    Thanks Techcapital
    Mar 19, 2014. 02:31 PM | Likes Like |Link to Comment
  • Investing In The Future: Illumina [View article]
    Excellent articles and very useful comments. You almost said it all. Our 1st target for ILMN was $150 and we did not change it when the stock crossed it. Our target for 2016 is more than double the 1st target. Important for investors is to not miss the future rallies in what we reiterated it is the engine of the biotech industry.
    Mar 13, 2014. 05:31 PM | 1 Like Like |Link to Comment
  • Geron's Promising News Poses No Threat To Incyte [View article]
    Jakafi results on polycythemia vera were published to day. We advise having a look. Also good luck for Geron. Still the title of this article seems to have said it all.
    Mar 7, 2014. 07:37 AM | 1 Like Like |Link to Comment
  • 3 Reasons To Stay Far Away From Synta Pharmaceuticals Stock [View article]
    Stock is trading over $6 now! There is reason for this, but it is scientific. Did you read the most recent news???
    Mar 2, 2014. 06:53 AM | Likes Like |Link to Comment
  • Geron's Promising News Poses No Threat To Incyte [View article]
    FACT: This discussion began on November 12 2013. The stock was trading at less than $39. The last posting was on Dec. 17, INCY had already added $7. Today is February 12, 2014, i.e.., less than three months later, the stock is trading over $69, adding $30 to stock price during this discussion.
    Feb 13, 2014. 06:23 AM | 1 Like Like |Link to Comment
  • The Hep C Race Is Heating Up: AbbVie Vs. Gilead [View article]
    That's true, not to forget ENTA, the brain behind the main drug used by ABBV.
    Feb 10, 2014. 08:18 AM | 3 Likes Like |Link to Comment
  • Pharmacyclics: Product Pipeline Overshadows Stock Market Influence [View article]
    A long-term growth, i.e., a sustained continuous rally for years to come. Companies like this one continue to evolve with the unprecedented scientific evolution. They are fishers of substance in the knowledge that inspires them to design better and better treatments until they reach their goal. Their goal is turning some deadly diseases into chronic diseases and offering cures for others, which is what is expected from the human brain's unlimited capability. Bottom line, PCYC will continue to rally as long as the firm continues to innovate. We have no reason to believe it will not continue to outperform.
    Feb 10, 2014. 01:04 AM | Likes Like |Link to Comment
COMMENTS STATS
151 Comments
68 Likes